Therapy Areas: Oncology
Mirati Therapeutics names new chairman of the board
20 February 2019 -

Mirati Therapeutics Inc (NASDAQ: MRTX), a clinical stage targeted oncology company, announced yesterday that it has named Faheem Hasnain as its chairman of the board, effective 15 February 2019.

Hasnain is the executive chairman of Gossamer Bio Inc. Prior to joining Gossamer Bio, he served as president, CEO and as a director of Receptos Inc from November 2010 to August 2015. Earlier, he was the president and chief executive officer and a director of Facet Biotech Corporation. He held that position from December 2008 until the company's acquisition by Abbott Laboratories in April 2010. Previously, he was president, chief executive officer and a director of PDL BioPharma Inc from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, he served at Biogen Idec Inc and most recently as executive vice president in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, he held roles with Bristol-Myers Squibb, where he was president of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organisations.

Charles M Baum, MD, PhD, president and chief executive officer of Mirati Therapeutics, said, 'I am thrilled to welcome Faheem to the board as chairman. I look forward to partnering with him as Mirati advances novel therapies like our KRAS inhibitor, MRTX849, through clinical development and towards anticipated market approval and becomes a world class oncology company. Faheem's proven track record of success in biotechnology and experience bringing novel and differentiated therapeutic products to the market will be invaluable as we advance our programs and strive to deliver important treatment options to patients and increase value for our shareholders.'

Login
Username:

Password: